ART RASTINEHAD, D.O.
Art Rastinehad, D.O. has accepted a new position at Northwell Health as System Director of Prostate Cancer and Vice Chairman of Lenox Hill Urology.
Art Rastinehad, D.O. recently accepted a position at Northwell Health as System Director of Prostate Cancer and Vice Chairman of Lenox Hill Urology. Dr. Rastinehad trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship-trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, laparoscopic and robotic surgery.
Dr. Rastinehad has dedicated his career to research and education. As a medical student he was awarded a full-scholarship to be a pre-doctoral teaching fellow in anatomy for his last three years of medical school. As a medical student Dr. Rastinehad joined the research group at the North Shore/Long Island Jewish (NSLIJ) Department of Urology and the Division of Interventional Radiology. His early research on Selective Arterial Prostatic Embolization (SAPE) for patients with refractory hematuria secondary to radiation prostatitis laid the foundation for his multidisciplinary approach,
subsequently completing an urology residency and interventional radiology fellowship at North Shore LIJ in 2009.
Dr. Rastinehad was then accepted into the Urologic Oncology and Image Guided Urology Fellowships at the National Institutes of Health. The NIH group that Dr. Rastinehad was a part of published the first MRI correlation using custom 3D based molds with prostate histopathology, which has helped lead to the widespread adoption of MR imaging in evaluating men at risk for prostate cancer.
After his NIH fellowship, Dr. Rastinehad returned to NSLIJ start the first hybrid Interventional Urology Program and validate the seminal work from the NIH with respect to prostate imaging and MR/US fusion guided prostate biopsies. He has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. An ongoing Phase III clinical trial using electromagnetic (EM) tracking devices for MR/Ultrasound fusion technology to improve prostate biopsy techniques has been led by Dr. Rastinehad since 2012.
Read More
In 2012, this was the first extramural trial of this technology in the United States outside the NIH. This new clinical approach is helping to lay the foundation for the evaluation of Focal Therapy, which only treats the diseased portion of the prostate. As of May 2016, Dr. Rastinehad was the first in the world to perform a gold nano-particle directed ablation for localized prostate cancer. This was performed using a novel transperineal EM tracked MR US fusion biopsy system that was developed by Dr. Rastinehad and Drs. Pinto, Wood and Choyke from the NIH.
Since medical school, education has always played a pivotal role in Dr. Rastinehad’s ethos. He has been the course director and/or faculty for more than 30 courses nationally and internationally. In 2014, he was the course director for the first MR/US fusion guided biopsy course supported by the AUA. He continues to meet the needs of the AUA members by leading the charge on educating urologists on how to read, segment and target suspicious areas of the prostate with mpMRI and ultrasound.
This past year, Dr. Rastinehad announced the world’s first joint fellowship in ‘Interventional Urology’. Continuing his goal to help bring these new treatments and approaches to the urologic community, he is developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety; this will provide a platform for urologists to leverage these technologies and perform interventional treatments in their own operating rooms.
Dr. Rastinehad’s research has been published in leading national and international medical journals. He has published over 75 articles and multiple text book chapters including Urinary Tract Imaging: Basic Principles: Campbells-Walsh Urology 11th and 12th Edition. Dr. Rastinehad is a leader in his field of Uroradiology and was the senior editor of the first comprehensive textbook on the subject, ‘Interventional Urology’, in 2016.
Dr. Rastinehad continues to dedicate his time to caring for patients by researching and developing new diagnostic and therapeutic interventions for urologic diseases, as well as training the next generation of urologists.
Show Less
UROLOGIC SURGEON
INTERVENTIONAL RADIOLOGIST
ART RASTINEHAD, D.O.
Art Rastinehad, D.O. is currently an Associate Professor of Radiology; Associate Professor of Urology and the Director of Focal Therapy and Interventional Urologic Oncology at the Icahn School of Medicine at Mt. Sinai.
Art Rastinehad, D.O. is currently an Associate Professor of Radiology; Associate Professor of Urology and the Director of Focal Therapy and Interventional Urologic Oncology at the Icahn School of Medicine at Mt. Sinai. Dr. Rastinehad trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship-trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, laparoscopic and robotic surgery.
Dr. Rastinehad has dedicated his career to research and education. As a medical student he was awarded a full-scholarship to be a pre-doctoral teaching fellow in anatomy for his last three years of medical school. As a medical student Dr. Rastinehad joined the research group at the North Shore/Long Island Jewish (NSLIJ) Department of Urology and the Division of Interventional Radiology. His early research on Selective Arterial Prostatic Embolization (SAPE) for patients with refractory hematuria secondary to radiation prostatitis laid the foundation for his multidisciplinary approach,
subsequently completing an urology residency and interventional radiology fellowship at North Shore LIJ in 2009.
Dr. Rastinehad was then accepted into the Urologic Oncology and Image Guided Urology Fellowships at the National Institutes of Health. The NIH group that Dr. Rastinehad was a part of published the first MRI correlation using custom 3D based molds with prostate histopathology, which has helped lead to the widespread adoption of MR imaging in evaluating men at risk for prostate cancer.
After his NIH fellowship, Dr. Rastinehad returned to NSLIJ start the first hybrid Interventional Urology Program and validate the seminal work from the NIH with respect to prostate imaging and MR/US fusion guided prostate biopsies. He has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. An ongoing Phase III clinical trial using electromagnetic (EM) tracking devices for MR/Ultrasound fusion technology to improve prostate biopsy techniques has been led by Dr. Rastinehad since 2012.
Read More
In 2012, this was the first extramural trial of this technology in the United States outside the NIH. This new clinical approach is helping to lay the foundation for the evaluation of Focal Therapy, which only treats the diseased portion of the prostate. As of May 2016, Dr. Rastinehad was the first in the world to perform a gold nano-particle directed ablation for localized prostate cancer. This was performed using a novel transperineal EM tracked MR US fusion biopsy system that was developed by Dr. Rastinehad and Drs. Pinto, Wood and Choyke from the NIH.
Since medical school, education has always played a pivotal role in Dr. Rastinehad’s ethos. He has been the course director and/or faculty for more than 30 courses nationally and internationally. In 2014, he was the course director for the first MR/US fusion guided biopsy course supported by the AUA. He continues to meet the needs of the AUA members by leading the charge on educating urologists on how to read, segment and target suspicious areas of the prostate with mpMRI and ultrasound.
This past year, Dr. Rastinehad announced the world’s first joint fellowship in ‘Interventional Urology’ at the Icahn School of Medicine at Mount Sinai. Continuing his goal to help bring these new treatments and approaches to the urologic community, he is developing the first Interventional Urology mobile platform combining image fusion, cone-beam CT/fluoroscopy, optical/EM tracking along with ESWL, ultrasound and the newest advances in radiation safety; this will provide a platform for urologists to leverage these technologies and perform interventional treatments in their own operating rooms.
Dr. Rastinehad’s research has been published in leading national and international medical journals. He has published over 75 articles and multiple text book chapters including Urinary Tract Imaging: Basic Principles: Campbells-Walsh Urology 11th and 12th Edition. Dr. Rastinehad is a leader in his field of Uroradiology and was the senior editor of the first comprehensive textbook on the subject, ‘Interventional Urology’, in 2016.
Dr. Rastinehad continues to dedicate his time to caring for patients by researching and developing new diagnostic and therapeutic interventions for urologic diseases, as well as training the next generation of urologists.
Show Less
Testimonials
Dr. Rastinehad was professional, efficient, and friendly. I arrived with a concern about flank pain and he put me at ease and helped coordinate further testing. I would recommend him highly.
Van T.
New York City
I was impressed just after my first visit. The doctor saw me right away and explained everything very clearly and called me the same day with test results.
Nicholas K.
New York City
Patient Reviews
All reviews have been submitted by patients after at least one visit and reflect each patient’s overall experience, wait time, and bedside manner.
CV + ACCOLADES
- Innovations
- Awards
- CV
- 1st in world MR US fusion guided electromagnetically tracked transperineal prostate biopsy
- 1st in the world Gold Nanoshell (particle) directed ablation of prostate tumors using MR US Fusion
- 1st Dual Fellowship trained interventional urologist
- 1st Textbook in field – Interventional Urology (Springer)
- 2019 AUA Young Urologist of the Year
- 2017 Best Paper Award: Nanoparticle Directed Ultra-Focal Laser Ablation of Prostate Tumors. Engineering and Urology Society, AUA 2017
- Fellow in the American College of Osteopathic Surgeons (FACOS), September 2016
- Prostate Cancer Foundation Young Investigator Award 2013: Evaluating the use of High-Resolution MRI / Multiphoton Microscopy (MPM) Ex Vivo Studies of Prostatic and Peri-Prostatic Tissue
- International Volunteers in Urology Med – Scholarship – Ajmer, India – December 2010, Volunteer Urologic Surgeon
- Pre-Doctoral Fellow/Instructor in the department of Anatomy at the New York College of Osteopathic Medicine – Full-Scholarship 2001-2004
- Academic Honor Society for the New York College of Osteopathic Medicine, Psi Sigma Alpha (~AOA) Membership, May 7, 2003
- Icahn School of Medicine at Mount Sinai, Department of Urology and Interventional Radiology, Associate Professor of Radiology and Urology Director of Focal Therapy and Interventional Urologic Oncology, January 5th, 2015 – Current
- Interventional Urology Fellowship Director 2018 – Current
- American Board of Urology #17506 Part 1 Exam July 2009 Passed, Part 2 Exam, February 2014 Passed
- Board Certified Examinations in Osteopathic Medicine (D.O.) 2004, COMLEX (Steps 1-3)
- Board Certified Examinations in Allopathic Medicine (M.D.) 2004, USMLE (Steps 1-3)
Clinical Trials
We believe in continued innovation in patient care. View our active trials.
Interventional Urology
We treat many urologic conditions with the most minimally invasive methods possible.
News
January 30, 2019
September 6, 2017
